The glycosylation pathways of several eukaryotic protein expression hosts are being engineered to enable the production of therapeutic glycoproteins with humanized applicationcustomized glycan structures. In several expression hosts, this has been quite successful, but one caveat is that the new N-glycan structures inadvertently might be substrates for one or more of the multitude of endogenous glycosyltransferases in such heterologous background. This then results in the formation of novel, undesired glycan structures, which often remain insufficiently characterized.
BACKGROUND
Glycosylation is the most widespread posttranslational modification of secreted and membraneassociated eukaryotic proteins. N-glycosylation is required for the efficient folding of many glycoproteins through the recruitment of calnexin/calreticulin-associated ERp57 protein disulfide isomerase (1) . For proteins that require such glycan-assisted folding, E. coli is unsuitable as an expression system and eukaryotic host cells are then used instead. However, different eukaryotic cells modify the N-glycans in various ways in the Golgi apparatus. For instance, yeasts generally produce high/hyper-mannose N-glycans that largely comprise of mannose, whereas mammalian cells produce mainly complex-type N-glycans, in which the glycan branches are modified with Nacetylglucosamine (GlcNAc), galactose (Gal), fucose (Fuc) and sialic acid (Sia). However, the pharmacokinetic and pharmacodynamic behavior of therapeutic glycoproteins is strongly influenced by the type of the glycans they carry. For example, yeast-produced high-mannose Nglycan modified glycoproteins are cleared from the bloodstream very rapidly through binding to (hepatic) macrophage lectins with mannose specificity (2) . This is disadvantageous if long circulatory half-life is desired, but advantageous if delivery to the macrophage endosomal system is intended, as is for example the case in Enzyme Replacement Therapy of Gaucher disease.
Nevertheless, yeast's native glycans can be immunogenic, and even when a high-mannose glycan is desired on the therapeutic glycoprotein, the yeast pathway needs to be significantly engineered to produce a human-type high-mannose structure, such as Man5GlcNAc2. Indeed, much work is being invested in such re-engineering of glycosylation pathways in eukaryotic expression host cells (3) . For fungal hosts such as Pichia pastoris, the common theme in most of these pathway engineering efforts consists of two parts. First comes the inactivation of the main host-cell specific glycosyltransferases which steer the host-specific pathway away from a glycan precursor structure that is common with the human pathway, resulting in the accumulation of this precursor. Most often, this is Man8GlcNAc2. Second, heterologous glycosidases and glycosyltransferases are introduced, which modify the common precursor to the desired structures (often mammalian-type high-mannose, hybrid or complex N-glycans). For instance, to reach the Man5GlcNAc2 structure, which is a high-affinity ligand for the macrophage mannose receptor, an α-1,2-mannosidase is targeted to the ER-Golgi boundary that converts Man8GlcNAc2 4 into Man5GlcNAc2. In previous work, we have named the resulting strain as 'GlycoSwitchM5'. The Man5GlcNAc2 glycan is also the starting substrate for the human N-glycosylation pathway, which can subsequently be introduced (4) .
Such N-glycan engineering has been thoroughly explored in Pichia pastoris, in our group and formerly at Glycofi Inc. (USA). Indeed, research demonstrated that strains can be obtained that produce human-type N-glycans. Nonetheless, the published data only report on a limited number of test-case proteins, and in most cases the glycan analytics were focused on the major glycan species, disregarding low abundant components in the mixture. The production of larger protein quantities (developed for true pharmaceutical use) enabled deeper analysis that often leads to the detection of unexpected glycoforms. Indeed, dozens of the host cell's endogenous glycosyltransferases remain active in the Golgi apparatus of the engineered cells (5) . For example, it has been described that glyco-engineered P. pastoris strains can incorporate β-1,2-linked mannose residues in some of their N-glycans (6), a modification believed to be only present on the outer chain of mannoproteins and O-glycans of wild-type Pichia-derived glycoproteins (7, 8) .
Reportedly, such structure has also been found on a human monoclonal IgG produced in glycoengineered P. pastoris (9) . The problem could be largely circumvented by identifying and then knocking-out the likely glycosyltransferase culprits. Nevertheless, it is clear that careful analysis remains necessary for each glycoprotein expressed in glyco-engineered strains.
Here the knowledge on this understudied aspect of glyco-engineering is extended by presenting the structural analysis of another unexpected N-glycan found on Pichia GlycoSwitchM5-produced interleukin-22 (IL-22), a member of the IL-10 superfamily of cytokines (10, 11, 12) . In the GlycoSwitchM5 strain, Man5GlcNAc2 typically makes up >80 % of all N-glycans on proteins produced (13) . However, this was decidedly different in the case of mIL-22, as reported in this study, offering an opportunity to perform detailed structural analysis of the off-target glycans.
RESULTS

Characterization of Pichia GlycoSwitchM5-produced mIL22
Interleukin-22 has three N-glycosylation consensus sites and all three can be modified with an Nglycan (14) . Murine IL-22 expressed in the wild-type GS115 strain appears as four major 5 molecular species on SDS-PAGE ( Figure 1 , A), ranging in molecular weight from approximately 17 to >40 kDa. The upper bands (bands 2, 3 and 4) disappear after PNGase F endoglycosidase digestion, which indicates that these are N-glycoforms of IL-22, whereas the lower band (band 1) corresponds to the non-N-glycosylated protein.
In parallel, a GlycoSwitchM5-mIL-22 expression strain was generated. Similar to wild-type produced mIL-22, purified GlycoSwitchM5-mIL-22 appears on SDS-PAGE as four major bands, ranging in molecular weight from 17 to about 25 kDa ( Figure 1 , A), all consistent with the modification of mIL-22 with a less heterogeneous (and lower molecular weight) N-glycan composition, as intended in this strain. Enzymatic removal of the N-glycans with PNGase F again resulted in a single non-N-glycosylated species. The bioactivity of mIL-22 was tested in a Ba/F3m22R cell proliferation assay and this showed that GlycoSwitchM5-produced mIL-22 is at least as active as mIL-22 produced in E. coli (specific activity of 7.9 U/µg for E. coli produced mIL-22 compared to 14.33 U/µg for GlycoSwitchM5 produced mIL-22).
Structural analysis of N-glycans of purified Man5GlcNAc2-mIL-22
After PNGase F release, the N-glycans were labeled and analyzed by fluorophore-assisted carbohydrate capillary electrophoresis on a DNA sequencer (DSA-FACE) (15) (Figure 1, B ). The electrophoresis profile showed that in addition to the expected Man5GlcNAc2 peak, a second major species migrated as a Man9-10GlcNAc2 N-glycan in the electrophoresis profile ( Figure 1 , B; lane 1). In order to gain more insight into the structure of this putative N-glycan, exoglycosidase digestions were performed. When digesting the N-glycans with α-1,2-mannosidase no shift was observed ( Figure 1, B ; lane 2). In contrast, the unknown N-glycan species had an increased mobility by about 1.5 glucose units upon Jack Bean α-mannosidase digestion (Figure 1 The apparently altered relative peak area of the two structures after Jack Bean digestion is due to the more efficient electro-kinetic injection of the very small tri-saccharide, which is inherent 6 to this analytical method. The loss of two α-mannosyl residues upon broad specificity αmannoside digestion is consistent with the hypothesis that the novel structure is likely a derivative of the Man5GlcNAc2 N-glycan in which one of the 3 terminal α-mannoses is modified. Next, the PNGaseF-released N-glycans were analyzed by MALDI-TOF MS (Figure 1 Supplementary Figure 1, A) . These results show that roughly ~20% of the sample consist of a Hex9GlcNAc2-type N-glycan relative to the Man5GlcNAc2 N-glycan ( Supplementary Figure 1, B ).
Moreover, a series of lower-abundance glycans were present with increments of one hexose residue up to Hex10GlcNAc2.
Finally, through GC-MS linkage analysis, the monosaccharide content of the N-glycan mixture and their linkage was determined (Supplementary Table 1 ). To this end, the permethylated N-glycans were acid hydrolyzed and the resulting sugar residues were analyzed by GC-MS. In addition to the expected linkages of mannose and GlcNAc in the main Man5GlcNAc2 N-glycan, also terminal glucose, 3-linked glucose, 2-linked mannose and 3-linked mannose was detected, with an approximated relative abundance ratio of 1:1:2:1. This is consistent with the CE and MS data that showed an abundance of the modified N-glycan of approximately 20-25% relative to the Man5GlcNAc2 N-glycan. Either one of the two 2-linked mannoses or the 3-linked mannose must be the mannose residue of the Man5GlcNAc2 structure that carries the linear tetra-hexoside substituent. Moreover, the data showed that a glucose residue is found at the terminus of this substituent. The presence of glucose residues in this glycan was particularly surprising, as it has never been described in N-glycans of mature, secreted proteins in this species.
NMR-spectroscopy
To further elucidate the structure of the substituent, an NMR analysis was performed on the PNGaseF released N-glycans, to reveal the sequence and the anomericity of the glycosidic linkages. First, a 1D 1 H-spectrum at 700 MHz was acquired. The analysis was performed on the mixture of N-glycans, as this assists in assigning the resonances belonging to the substituent based on the relative peak intensities. Upfield in the 1D 1 H-spectrum, the signals that correspond 8 to the methyl groups of the acetyl-function of the 2 GlcNAc-residues can be distinguished (1.8 - Figure 2 ). In the anomeric region, 4 anomeric signals were eliminated from further consideration based on their very low intensities relative to the other anomeric signals ( Figure 2 , A; top trace). These very low intensity anomeric signals likely come from a small percentage of native Pichia N-glycans, containing 2-linked and 2,6-linked mannose, as seen in the linkage analysis. Furthermore, diffusion analysis was used to eliminate two more signals that do not belong to any of the N-glycan species but originate from smaller saccharide constituents present in the sample, possibly degradation products (Supplementary Table 2 , marked with * and **). Exclusion of these contaminants leaves 12 signals (A-L).
ppm) (Supplementary
Then, Total Correlation Spectroscopy (TOCSY) was used to identify the monosaccharide constituents of the tetra-saccharide substituent on the Man5GlcNAc2 N-glycan based on the 12 remaining anomeric signals ( Figure 2 , A). The specific stereochemistry of different monosaccharides causes a distinct TOCSY-trace for each, which allows for a relatively easy identification (16) . The TOCSY traces of B, C and J (Figure 2 , A; green traces) have a single crosspeak, which is characteristic for the β-D-mannose stereochemistry. Based on the integrated peak intensity, residue J is the β-mannose in the core of the N-glycans, which is common to all, whereas B and C have a lower peak intensity, consistent with these being part of the Hex9GlcNAc2 glycan. Thus, both 2-linked mannose residues in the tetra-saccharide substituent are β-linked. A typical TOCSY pattern for monosaccharides of D-glucose geometry has three or more distinct crosspeaks of similar intensity and the crosspeaks tend to be very broad (because of overlapping ringproton resonances). Such distinct traces are found for A, D and E, as well as for K and L. Based The common Man5GlcNAc2 core-structure consists of 4 α-D-mannoses and a single β-D-mannose, in addition to one β-GlcNAc (with β-glucose ring geometry) and the reducing terminus GlcNAc which can be both the α-or β-epimer. Based on the high intensities of the anomeric resonances: 9 F, G, H and I originate from the 4 α-mannose residues in the common core, J is from the βmannose residue, L is from the β-GlcNAc, and H is from the β-anomer of the reducing-end GlcNAc. One of either A, D or E is from the α-anomer of the reducing-end GlcNAc. This allows to conclude that the four monosaccharides that constitute the tetra-hexoside are a terminal αglucose, two 2-linked β-mannoses and a 3-linked α-glucose. Heteronuclear Single Quantum Coherence (HSQC) spectroscopy indeed confirmed the monosaccharide content of the tetrasaccharide, and it also allowed to determine the type of linkages within the tetrasaccharide ( Supplementary Table 3 ). One glucose residue was placed on the most distal end in an α-linkage, whereas the other 3-substituted glucose residue is α-1,3connected to a terminal mannose of the Man5GlcNAc2 core. In between both glucose residues, there are two β-linked mannose residues, bound on the anomeric carbon (C1) and at their C2 position. This set of constraints leaves only 1 possible structure, i.e. Glcα-1,2-Manβ-1,2-Manβ-1,3-Glcα-1,3-Manα1-R (Figure 2, B ).
Characterization of GlycoSwitchM5-hIL-22
Murine IL-22 and human IL-22 have a high amino acid sequence similarity (>80%). Therefore, it was investigated whether GlycoSwitchM5-produced hIL-22 carries similar N-glycans as found on mIL-22. G115-and GlycoSwitchM5-produced hIL-22 leads to a comparable SDS-PAGE pattern as compared to mIL-22 (data not shown), and Man5GlcNAc2-hIL-22 is also functionally active (specific activity of 6.5 U/µg for E. coli produced hIL-22 compared to 19.37 U/µg for GlycoSwitchM5 produced hIL-22).
The GlycoSwitchM5-hIL-22 was purified, and its N-glycan composition was analyzed by DSA-FACE, as described above. This revealed a second major peak in addition to the expected Man5GlcNAc2 peak, however this N-glycan was situated around 9 glucose units. A lower abundant peak was also present just above 10 glucose units, quite similar to the one found on Given the similarities between mIL-22 and hIL-22, the N-glycans of hIL-22 were analyzed to investigate whether the glycans were structurally similar to those from mIL-22. MALDI-TOF MS analysis showed that the dominant species was Hex5GlcNAc2 (m/z 1256. 35 ), next to two other species with m/z 1742.5 (Hex8GlcNAc2) and 1904.5 (Hex9GlcNAc2) ( Supplementary Figure 3 , A).
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MS/MS analysis of the peak at m/z 1904.5 gave a very similar fragmentation pattern as observed for the same glycan species of mIL-22 ( Supplementary Figure 3, B ).
We conclude that GlycoSwitchM5-hIL-22 is modified with similar off-target N-glycans as GlycoSwitchM5-mIL-22, with a different species along its biosynthesis route dominating, depending on the protein. 
Overcoming unwanted N-Glycosylation
One way of dealing with undesired N-glycans is to eliminate the N-glycan sites that carry them.
To determine whether the additional N-glycan species are restricted to a specific site, three Nglycosylation site mutants of hIL-22 were constructed, each having one intact N-glycosylation site (N21, N35 or N64 of the mature hIL-22) and two Asn-to-Gln N-glycosylation site mutations. When these mutants were expressed in a GlycoSwitchM5 background, only the hIL-22 mutant with the intact N35-glycosylation site had the prominent peak around Man8GlcNAc2 on DSA-FACE ( Figure   4 , A), demonstrating that this modification is indeed site-specific.
Another way of dealing with interference by endogenous glycosyltransferases is to outcompete them with heterologous glycosyltransferases with a similar acceptor substrate specificity. Here, the overexpression of the human N-acetylglucosaminyltransferase I (hGnT-I) was tested to see whether it is able to suppress the presence of undesired glycan species. GnT-I places a β-1,2linked GlcNAc on the inner α-1,3 arm of the Man5GlcNAc2-core. In the strains overexpressing GnT-I, the N-glycans found on hIL-22 consisted predominantly of GlcNAcMan5GlcNAc2 (Figure 4 , B; lane 1), and the peak corresponding to the glycan described above disappeared.
Exoglycosidase digestion with β-N-acetyl-hexosaminidase confirmed this glycan modification by shifting the mobility back to Man5GlcNAc2 (Figure 4 
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DISCUSSION
An eukaryotic host such as yeast for the expression of IL-22 can be useful since N-glycosylation can enhance the bioactivity of IL-22 (17) , and IL-22 is currently being explored as a therapeutic protein (18) . Therefore, the secretory expression in P. pastoris was explored and this showed that the glycoforms from human or mouse IL-22 had superior bioactivity compared to unglycosylated IL-22 produced in E. coli, demonstrating the value of the Pichia expression system. On the other hand, the presence of a variety of wild-type oligo-mannose N-glycans introduces considerable recombinant protein heterogeneity. To overcome the N-glycan associated heterogeneity, glycoengineered Pichia strains are used. Previous studies have explored recombinant protein production in the GlycoSwitchM5 strain (13, 19, 20) . Here the same technology was used in an attempt to express IL-22 glycoforms modified with Man5GlcNAc2 N-glycans. However, in addition to the expected Man5GlcNAc2 N-glycan, other abundant N-glycoforms were detected.
The N-glycans on glycoproteins produced by P. pastoris typically consist of α-linked mannose residues (21) . Previously, an α-mannosidase recalcitrant Hex9GlcNAc2 N-glycan on a recombinant immunoglobulin G (IgG) from glyco-engineered Pichia was described by Gomathinayagam et al. (9) . Recalcitrance to exoglycosidase digestion was reportedly due to the presence of consecutive β-linked mannose residues, which results from β-1,2-mannosyltransferase-activity that normally occurs on the outer chain of N-glycans (and O-glycans) in wild-type P. pastoris (7, 8) . Here too, the unexpected N-glycans were recalcitrant to α-1,2 mannosidase digestion. Therefore, we initially assumed a similar structure. This was still largely in agreement with the MALDI-MS/MS data, showing a linear tetra-saccharide substituent on the termini of the Man5GlcNAc2 N-glycan.
The structure identified by Gomathinayagam et al. appeared to be capped with a single α-1,2mannose residue, although the authors remarkably reported that the N-glycan was recalcitrant to digestion with α-1,2 mannosidase. However, the unknown IL-22 N-glycan that we describe here was found to be capped with a glucose-residue, explaining the lack of sensitivity for αmannosidase digestion. Glucose-residues have been reported on the outer chain of wild-type Pichia mannoproteins but they are linked through a phosphodiester linkage (8) . A 'capping glucose' has been described in Yarrowia lipolytica as a consequence of impaired ER-processing by glucosidase-II in glyco-engineered Δalg3 strains (22) . Nevertheless, the structural data obtained by MALDI-MS/MS did not support an ER-type N-glycan.
In addition to exoglycosidase digestion and chemical linkage analysis, 1D and 2D NMRapproaches were used to elucidate more structural details of this N-glycan (6, 8, 9, 23) . Although The reported structure deviates considerably from what was published before (9) . Pichia βmannosyltransferases (BMT) are believed to add two consecutive β-1,2-linked mannose residues (6), whereas here a β-1,2-and a β-1,3-linked mannose was present, challenging this hypothesis.
Only the homologous Candida albicans BMT1 enzyme has been biochemically studied. Analysis of C. albicans BMT1 showed that it transfers two consecutive β-1,2-mannose residues in vitro.
The authors speculated that in vivo only a single β-mannose would be transferred by a single BMT because of competition with other endogenous mannosyltransferases present in the Golgi (24) .
This might be consistent with our observations where two different BMTs might act sequentially, and therefore two distinct β-mannose linkages are present in the identified structure. It is clear that more is warranted on the specificity of Pichia BMT enzymes in the future.
Equally puzzling is the presence of the glucose residues. The GlycoSwitchM5 strain overexpresses an HDEL-tagged α-1,2-mannosidase retaining this enzyme at the ER-Golgi boundary (19) . Hence, transfer of the initiating α-1,3-linked glucose residue likely occurs at the same stage of the secretory system (or beyond) in the Golgi compartments. In the ER, the glucosyltransferases Alg6p and Alg8p take part in the dolichol-linked assembly of the precursor oligosaccharide.
However, it would appear unlikely that glucosylation of the newly identified N-glycan initiates in the ER, since the addition of the linear saccharide can be outcompeted by co-expressing a Golgi localized hGnT-I. To date, no Golgi-localized α-glucosyltransferases have been described. Another hypothesis might be that the Man5GlcNAc2 N-glycan, while still in the ER, is a substrate for Pichia UGGT (UDP-glucose:glycoprotein glucosyltransferase) which is part of the calnexin folding cycle (25). Interaction with UGGT is not solely dependent on the N-glycan moiety but is also governed by protein-protein interactions, perhaps allowing for some promiscuity in the glycan substrate, as has been described for Trypanosomal UGGTs. However, another explanation is that yet unknown glucosyltransferases are present in the Pichia Golgi, especially for the most distal glucose residue which must be transferred by a transferase which acts downstream of Golgilocalized β-mannosyltransferases.
If glycoproteins are modified with undesired N-glycan modifications, mutagenesis of the affected site is by far the easiest method to deal with this, as long as the function of the protein permits it. By doing so, the α-mannosidase recalcitrant N-glycan could be traced back to the single site N35 on the mature hIL-22. Remarkably, a recent report on IL-22 produced in planta, showed that N35 was particularly prone to α-1,3 core fucosylation, especially when N21 was not occupied (26) . Although it is unclear why only this specific N-glycosylation site is affected in hIL-22, it has been reported that the local protein surface topology as well as glycan-protein interactions or surface charge may modulate protein-or glycan-glycosyltransferase interactions and determine N-glycosylation site specific interactions (26, 27) , which could also explain some differences between human and mIL-22. Nevertheless, eliminating the site at N35 seems to effectively abolish the formation of the recalcitrant N-glycan.
The tetrasaccharide modification could also be outcompeted by functional overexpression of hGnT-I. This provides for indirect evidence that the modification may have been linked to the inner α-1,3-mannose of the Man5GlcNAc2 structure as it is this residue that is modified by GnT-I.
As GnT-I overexpression is the next step in the synthetic biology pathway towards human complex-type glycans (4), the formation of the off-target glycans that we describe here is strongly suppressed in these humanized strains, although it will likely not always be totally absent.
CONCLUSION
In summary, our results show that the non-yeast native oligosaccharides resulting from in vivo trimming of Man8GlcNAc2 to Man5GlcNAc2 by an ER/Golgi-retained α-mannosidase serve as substrates for endogenous glycosyltransferases, creating potentially immunogenic neoglycoforms. Although GlycoSwithM5-engineered Pichia strains usually modify their glycoproteins 16 with predominantly the Man5GlcNAc2 N-glycan structure, our results demonstrate that this should be validated by careful N-glycan analysis, especially if the glyco-engineered products are to be used as biopharmaceuticals. Further innovation would be welcome to robustly remove or preclude the synthesis of these off-target high-mannose-type neo-glycans, regardless of their structure.
MATERIALS AND METHODS
Genetics and clone generation
Escherichia coli (E. coli) MC1061 or DH5α was used as the host strain for recombinant DNA manipulations. E. coli were cultivated in LB medium supplemented with the appropriate antibiotics: 100 μg/mL carbenicillin (Duchefa Biochemie) or 50 µg/mL Zeocin® (Life Technologies) depending on the required selection.
The Pichia pastoris GS115-strain (Life technologies) was used for protein expression and is the starting strain for glyco-engineering. P. pastoris cells were grown in liquid YPD or solid YPD-agar and selected for with the appropriate antibiotics: 100 µg/mL Zeocin® or 300 µg/mL BlasticidinS-HCl (Sigma Aldrich). Transformants of auxotrophic strains were selected on Complete Supplemented Medium (CSM) lacking Histidine (0.077% CSM-HIS, 1% D-glucose, 1.34% Yeast Nitrogen Base, 1.5% agar). Bacto yeast extract, Bacto tryptone, Bacto peptone, Bacto agar and Yeast Nitrogen Base (YNB) were purchased from Difco (Becton Dickinson). For protein expression, biomass was grown on BMGY. For induction, the cultures were switched to BMMY.
Plasmid construction
pPIC9mIL22. The sequence corresponding to mature mIL-22 (UniProt accession Q9JJY9, residue 34-179) was PCR amplified using primer mIL22XhoIS and mIL22NotIAS (Supplementary Table 4 ) and subsequently cloned as an XhoI/NotI fragment in the similarly opened pPIC9 expression vector for P. pastoris resulting in the vector pPIC9mIL22, containing the mature mIL-22 coding sequence downstream of the strong methanol inducible AOX1-promoter and in-frame with the Saccharomyces cerevisiae α-mating factor for secretion into the culture supernatant. Selection in P. pastoris was carried out using the HIS4 auxotrophic marker. Proper insert orientation was verified by restriction enzyme analysis and by Sanger sequencing using the 5'AOX1 and 3' AOX1 primers.
pPIC9hIL22. The ORF corresponding to the mature form of human interleukin-22 (hIL-22, UniProt accession Q9GZX6, residue 34-179) was codon optimized for P. pastoris using Genscript's proprietary algorithm and ordered synthetically as pUC57-hIL22. The hIL-22 ORF was flanked with XhoI and NotI sites to clone in-frame with the S. cerevisiae α mating factor in the XhoI/NotIopened pKai and pPIC9 expression vector (28) . Expression of hIL-22 in both pPIC9-hIL22 and pKai-hIL22 is under control of the AOX1 promoter. The pKai-hIL22 has a Zeocin ® resistance marker for selection.
Construction of hIL22 N-glycosylation site mutants
The PCR-based Quick change site directed mutagenesis kit (Agilent) was used to remove Nglycosylation sites from the hIL-22 ORF by mutating the Asn residue of the Asn-X-Ser/Thr consensus sequence to Gln ( Supplementary Table 4 ). By the sequential mutagenesis of the different N-glycosylation sites from pUC57-hIL22, variants were obtained that each have only a single N-glycosylation site (N21, N35 or N64). These constructs are named pUC57-IL22N21, pUC57-IL22N35 and pUC57-IL22N64 referring to the N-glycosylation site that was left intact. Each construct was sequence verified by Sanger sequencing using custom primers IL22FW and IL22RV (Supplementary Table 4 ). The constructs were then cloned in the pKai-expression vector as described above, yielding vectors pKai-IL22N21, pKai-IL22N35 and pKai-IL22N64. Each expression construct was sequence verified using the standard 5' AOX1 primer and 3'AOX1 primer.
Pichia transformation and strain generation
Pichia transformation was performed as described previously (29) . All constructs were linearized to facilitate directed genomic integration. The pPIC9mIL22 vector was SalI linearized in the HIS4 marker whereas pKaiIL-22 and pPIC9-hIL22 expression constructs were PmeI-linearized in the AOX1-promoter prior to electroporation to the GS115 strain. For glyco-engineering of mIL-22, the GS115-strain expressing mIL-22 was transformed with the BstBI-linearized pGlycoSwitchM5 plasmid. The pGlycoSwitchM5 disrupts the OCH1 gene and introduces a constitutively expressed α-1,2-mannosidase in the ER (4), generating the Man5-mIL22-strain that modifies its glycoproteins with Man5GlcNAc2. Transformation of the Man5-strain with SalI-linearized pGlycoSwitchGnT-I resulted in strain GnMan5 strain that modifies its proteins predominantly with GlcNAcMan5GlcNAc2. For glyco-engineering of hIL-22, the pPIC9hIL-22 was transformed to a GlycoSwitchM5 strain, which is a GS115 strain previously transformed with the BstBI-linearized pGlycoSwitchM5 plasmid (4) . Similarly, to generate the GnMan5-hIL-22 expression strains, the pPIC9hIL-22 expression construct was transformed to a GlycoSwitchM5 strain previously transformed with the pGlycoSwitchGnT-I (4, 19) . Transformants were grown on minimal dropout media (CSM-HIS) or YPD-agar containing the appropriate antibiotics, and were screened for IL-22 expression.
IL-22 production in Pichia pastoris
Cells were grown in BMGY medium for 48 hours at 28°C (250 rpm), after which protein expression was induced by changing the growth medium to BMMY. The induction was maintained for 48 hours by spiking the cultures 2-3 times daily with 1% methanol. For clone screening, the cells were removed by centrifugation (1, Finally, hIL-22 containing fractions were collected and concentrated for further analysis.
Protein deglycosylation
For DSA-FACE and MALDI-TOF MS N-glycosylation profiling, IL-22 was first denatured in 0.5% SDS, The released N-glycans were purified and cleaned using Carbograph Porous Graphitized Carbon (PGC) Extract-Clean columns (Alltech Associates Inc) (31, 32) .
MALDI-TOF MS
Prior to loading, the PGC columns were conditioned with 3 × 500 µL 80% acetonitrile, 0.1% TFA in MilliQ H2O and equilibrated with 3 × 500 µL of MilliQ H2O. After sample loading, the columns were washed with 3 × 500 µL of MilliQ H2O and free N-glycans were eluted with 3 × 500 µL of 25% acetonitrile, 0.05% TFA in MilliQ H2O. The eluate was pooled and evaporated to dryness.
For MALDI MS characterization, the underivatized N-glycans were spotted on a MALDI-target and mixed 1:1 with 70% MeOH, 20 µM NaCl and 20 mg/mL DHB-matrix. MALDI mass spectrometric analyses were performed on an Applied Biosystems 4800+ Proteomics Analyzer with TOF/TOF optics (Applied Biosystems, Foster City, CA). This mass spectrometer uses a 200 Hz frequency tripled Nd:YAG laser operating at a wavelength of 355 nm.
DSA-FACE glycan analysis
APTS derivatized N-linked oligosaccharides were analyzed by DSA-FACE on a ABI 3130 capillary DNA sequencer as described previously (15) . N-glycans of bovine RNaseB and a dextran ladder 
Permethylation, mass spectrometrical analysis and linkage analysis of permethylated glycans
Permethylation of the lyophilized glycans was performed according to the procedure developed by Ciucanu and Kerek (33) . The reaction was terminated by adding 1 mL of cold 10% (v/v) acetic acid followed by three extractions with 500 µL of chloroform. The pooled chloroform phases were then washed eight times with water. The chloroform phase containing the methylated derivatives was finally dried under a stream of nitrogen and the extracted products were further purified on a C18 Sep-Pak (24) . The C18 Sep-Pak was sequentially conditioned with methanol (5 mL), and water (10 mL). The derivatized glycans dissolved in methanol were applied on the cartridge, washed with 3 x 5 mL water, 2 mL of 10% (v/v) acetonitrile in water and eluted with 3 mL of 80% (v/v) acetonitrile in water. The acetonitrile was evaporated under a stream of nitrogen and the samples were freeze-dried. MALDI-TOF-MS and linkage analyses of permethylated glycans were performed as described elsewhere (34) .
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NMR analysis
All NMR spectra were measured on a Bruker Avance II NMR spectrometer operating at frequencies of 700.13 MHz and 176.05 MHz for 1 H and 13 C respectively. All measurements were performed using a 1 mm TXI 1 H-13 C/ 15 N Z-gradient probe for maximal signal intensity. For sample preparation, the lyophilized N-glycans were dissolved in 10 µl of 99.9% D2O. 2,2-dimethyl-2silapentane-5-sulfonate (DSS) was used as an internal chemical shift standard and 1 µl of NaN3 was added to prevent microbial growth. The mixture was then transferred to a 1 mm capillary tube (Bruker). All measurements were performed at 50°C to minimize overlap between the residual water signal and those of the N-glycan.
The 2D COSY (Correlation Spectroscopy), TOCSY (Total Correlation Spectroscopy), 1 ppm. Data were multiplied using a squared sine window (COSY) or a squared cosine window (TOCSY and NOESY) before zero-filling to a 2048 by 2048 real data matrix. A second order polynomial baseline correction was performed on both the F1 and F2 dimension. For heteronuclear 2D experiments, a 13 C spectral width of 160 ppm (gHSQC) and 220 ppm (gHMBC) was used, and 8 to 64 scans were accumulated for each of the 512 increments. Data were multiplied with a squared sine window, followed by zero filling as before, and Fourier Transformation followed by second order baseline correction, when necessary.
Interleukin-22 bio-activity assay
The biological activity of both murine and human Man5GlcNAc2-IL-22 was determined using the mouse pro-B cell line Ba/F3m22R (Ba/F3 cells expressing the mouse IL-22 receptor (IL22R1) as described in (35); Ba/F3m22R cells were seeded in 96-well plates at a concentration of 3000 cells per well in the presence of dexamethasone. Three days after addition of serial sample dilutions, 22 cell growth was measured by colorimetric determination of hexosaminidase levels according to Landegren (36) . The EC50 was determined based on the dose-response curve and the specific activity was calculated as A(U/mg)=(1/EC50)*10 6 . Mouse IL-22 expressed in E. coli (ECmIL-22) was purified as described previously (37) and was used as control.
